HCP1306

DRUG5 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyPrimary Hypercholesterolemia

Phase 1

Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

CompletedNCT02941848

Hanmi Pharmaceutical Company LimitedPrimary Hypercholesterolemia

Start: 2014-11-30End: 2015-01-31Updated: 2016-10-21

A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.

CompletedNCT04081844

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2018-05-03End: 2018-06-28Updated: 2019-09-09

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

CompletedNCT04322266

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2018-12-21End: 2019-02-13Updated: 2020-03-26

A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

CompletedNCT06518122

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2024-09-01End: 2025-01-03Updated: 2025-02-20

A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers

Not yet recruitingNCT07297693

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2025-12-19End: 2026-04-10Target: 60Updated: 2025-12-22

Related Papers

Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants.

2024-05-22

Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects.

2017-08-1015 citations